Dr Gideon Hirschfield MA MB BChir FRCP PhD

Dr Gideon Hirschfield

Institute of Immunology and Immunotherapy
Senior Lecturer/Honorary Consultant Transplant Hepatologist

Contact details

Centre for Liver Research
NIHR Birmingham Liver Biomedical Research Unit
Institute of Immunology and Immunotherapy
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Gideon is a clinician and academic with a special interest in Hepatology, including in particular autoimmune liver disease, as well as the conduct of clinical trials in liver disease generally. He is well published scientifically and clinically in his field having made important contributions to the understanding and clinical management of diseases such as primary biliary cholangitis/cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis. He joined Birmingham in 2012 after just over 4 years in Toronto where he focussed heavily on the genetics of autoimmune liver disease. His overarching goal is to continue the translation of scientific advances towards new rational therapies for patients with chronic inflammatory liver diseases.


  • Senior Lecturer
  • MB BChir 1996
  • MRCP 1999
  • PhD 2006


Gideon Hirschfield graduated from Trinity College Oxford in 1994 (having been awarded the University of Oxford Wronker Prize for most outstanding performance in the Final Honour School), and subsequently from Cambridge where he completed his clinical studies with distinction. He undertook junior medical posts at the Hammersmith and Royal Brompton hospitals before moving to a MRC Clinical Research Fellowship at UCL. There he worked within the uniquely translational National Amyloidosis Centre/Centre for Acute Phase Proteins, with Sir Mark Pepys FRS as his supervisor. His PhD was focussed on the development of inhibitors of C-reactive protein. He completed his advanced Gastroenterology and Hepatology training in Cambridge, and was awarded Specialist status in 2007. Until January 2012 he worked in Toronto, Canada, where he was a Staff Physician and Assistant Professor of Medicine at the University Health Network and University of Toronto. During this time he managed one of the largest autoimmune liver disease cohorts in North America, and with his colleague Prof Kathy Siminovitch published the seminal genetic observations underpinning the IL-12 signalling axis as critical to the pathophysiology of PBC. He now divides his time between translational research in autoimmune liver disease, and his clinical, Transplant/Hepatology, practice at the QE hospital. In particular the cohorts of patients with PBC, PSC and AIH he manages are some of the largest internationally, providing Gideon unique clinical skills in their management and recruitment to clinical trials of novel therapies.


Postgraduate supervision

Gideon is interested in supervising doctoral research students in the following areas:

• The pathophysiology and clinical management of autoimmune liver disease.

If you are interesting in studying any of these subject areas please contact Gideon on the contact details above.


Autoimmune liver disease, Genomics, Clinical Trials, Immunology

Translational research looking to understand how the pathophysiologic basis of autoimmune liver disease can be better understood to the benefit of patients requiring more rational therapy.

Other activities

  • Medical Advisor AIH, PSC and PBC patient support groups
  • Consultant QE Hospital (Hepatology/Liver Transplantation)
  • Consultancy to Pharma on design and conduct of clinical trials in autoimmune liver disease, including regulatory advice
  • Teaching nationally and internationally
  • Media comments on liver disease
  • CRN Lead (Hepatology), West Midlands


For a Pubmed summary of Gideons’ latest publications please see: http://www.ncbi.nlm.nih.gov/pubmed/?term=hirschfield+g 

For Gideon’s Research Gate page please see: https://www.researchgate.net/profile/Gideon_Hirschfield 

For his work on PBC and PSC in the UK please follow the following links: 

Webb G, Chen YY, Li KK, Neil D, Oo YH, Richter A, Bigley V, Collin M, Adams DH, Hirschfield GM. Single-gene association between GATA-2 and autoimmune hepatitis: a novel genetic insight highlighting immunologic pathways to disease.  J Hepatol. 2016 Jan 23. pii: S0168-8278(16)00051-9. doi:10.1016/j.jhep.2016.01.017. 

Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, Nnane IP, Dasgupta B, Li K, Selmi C, Marschall HU, Jones D, Lindor K; PURIFI Study Group. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to Ursodeoxycholic Acid: a proof-of-concept study. Hepatology. 2015 Nov 24. doi:0.1002/hep.28359. 

Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL,Floreani A, Ponsioen CY, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, BurroughsAK, Mason AL, Kowdley KV, Kumagi T, Harms MH, Trivedi PJ, Poupon R, Cheung A,Lleo A, Caballeria L, Hansen BE, van Buuren HR; Global PBC Study Group. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology. 2015 Dec;149(7):1804-1812.e4. 

Liaskou E, Henriksen EK, Holm K, Kaveh F, Hamm D, Fear J, Viken MK, Hov JR, Melum E, Robins H, Olweus J, Karlsen TH, Hirschfield GM. High-throughput T-cell receptor sequencing across chronic liver diseases reveals distinct disease-associated repertoires. Hepatology. 2015 Aug 7. doi: 10.1002/hep.28116. 

Trivedi PJ, Lammers WJ, van Buuren HR, Parés A, Floreani A, Janssen HL, Invernizzi P, Battezzati PM, Ponsioen CY, Corpechot C, Poupon R, Mayo MJ, Burroughs AK, Nevens F, Mason AL, Kowdley KV, Lleo A, Caballeria L, Lindor KD,Hansen BE, Hirschfield GM; Global PBC Study Group. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016 Feb;65(2):321-9. 

Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV,Vincent C, Bodhenheimer HC Jr, Parés A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Böhm O, Shapiro D. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology. 2015 Apr;148(4):751-61. 

Liaskou E, Jeffery LE, Trivedi PJ, Reynolds GM, Suresh S, Bruns T, Adams DH,Sansom DM, Hirschfield GM. Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology. 2014 Jul;147(1):221-232.e7. 

View all publications in research portal


Gideon Hirschfield is an expert in the management of advanced liver disease and liver transplantation.  In particular he has a global recognition and expertise in autoimmune liver disease (primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis) including the development of new therapies for patients. 

Media experience

He has contributed expert opinion and advice to the media previously including the BBC, as well as contributing to video promotion of the Liver Biomedical Research Unit at the University.


Liver disease

Stratified medicine in rare liver disease